Testing eravacycline for kids with serious belly infections
Part of Digestive system, Infections clinical trials.
This trial tests an antibiotic called eravacycline for children (ages 8–17) with serious belly infections. The medicine is given through an IV in the hospital to see if it is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 8 and 17 years old and in the hospital for a severe belly infection (like a ruptured appendix or a belly abscess).
- Your child will need to stay in the hospital for at least 4 days and will receive the study drug (eravacycline) through an IV line for up to 14 days.
- Your child’s kidneys must be working well (eGFR above 50).
- Your child cannot have taken certain antibiotics (tetracyclines) in the last 2 weeks or have a known allergy to tetracyclines.
- Your child cannot be pregnant or breastfeeding, and if sexually active, must agree to use two forms of birth control.
- Your child cannot have a weakened immune system (like from an organ transplant, cancer treatment, or long-term high-dose steroids).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibiotic called aztreonam-avibactam (ATM-AVI) for treating serious bacterial infections in hospitalized babies under 9 months old. The goal is to see if it's safe and works well.
This study looks at how well the antibiotic eravacycline works in seriously ill patients who have not improved with other antibiotics. It aims to understand how the drug behaves in the body to help guide dosing and improve treatment.
This trial tests a new antibiotic combination (meropenem and pralurbactam) for people with serious infections inside the belly (abdomen). It aims to see if this treatment is safe and works better than current options.
This study tests a combination treatment using eravacycline, an antibiotic, for pneumonia caused by bacteria that are resistant to many other antibiotics. It aims to see if this treatment can help patients who have not responded to standard care.
This trial is checking how well a combination of two antibiotics, aztreonam and avibactam, works in patients who have a specific type of drug-resistant bacterial infection in the belly or lungs. It aims to offer a new treatment option for infections that are hard to cure.
This trial tests whether one dose of intravenous (IV) antibiotics is as effective as the usual multiple-dose course for children with complicated urinary tract infections (UTIs) who need IV treatment in the emergency department. It aims to reduce hospital stays and the need for repeated IV lines.
Hear when a new Complicated Intra-abdominal Infections (cIAI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.